Aryabhatta Sadhu: Which Part of Haemostasis Has Failed First?
Aryabhatta Sadhu, Attending Consultant and Head of Transfusion Medicine at Fortis Hospital Shalimar Bagh, New Delhi, shared a post on LinkedIn:
“A bleeding patient with ‘acceptable’ platelets can still be haemostatically unsafe.
One common error in active bleeding is looking at haemoglobin and platelet count first, while fibrinogen is checked late – or corrected even later.
That is backwards physiology.
In major bleeding, fibrinogen is often one of the earliest haemostatic factors to fall.0
A patient may have a platelet count of 70,000–90,000/µL and still continue bleeding because the clot being formed has poor fibrin strength.
The clinical decision point is simple:
Before reflexively asking for ‘2 FFP and 1 platelet,’ ask:
What is the fibrinogen?
If the patient is actively bleeding and fibrinogen is low, correction with cryoprecipitate or fibrinogen concentrate should be considered early, depending on local availability and protocol.
This is even more critical in obstetric haemorrhage, trauma, liver disease, cardiac surgery, DIC-like states, and massive transfusion scenarios.
Platelets are not cement by themselves.
FFP is not a universal correction fluid.
Cryoprecipitate is not a ‘last step’ component.
A bleeding patient needs haemostatic reconstruction: red cells for oxygen carriage, plasma factors when coagulation is globally impaired, platelets when primary haemostasis is inadequate, fibrinogen when clot strength is failing, calcium when citrate load rises, and temperature/pH correction because enzymes do not work in a hostile physiology.
Practical takeaway:
In active bleeding, do not treat the CBC alone.
Ask for:
- PT/INR
- aPTT
- fibrinogen
- platelet count
- ionised calcium
- ABG/lactate
- TEG/ROTEM if available
The question is not ‘Which blood component is pending?’
The question is:
Which part of haemostasis has failed first?
That is where Transfusion Medicine must move beyond blood issue and function as bedside haemotherapy consultation.”

Other posts featuring Aryabhatta Sadhu with Hemsotasis Today.
-
Nov 17, 2026, 05:47Multidisciplinary Teams Kick Off SAHF MASAC ES 2026 with Pre-Symposium Workshops – South African Haemophilia Foundation
-
Nov 17, 2026, 05:41Boitumelo Malatji: South African Delegation Advances Advocacy Strategies at NNHF Southern Africa Workshop
-
Nov 17, 2026, 05:36Joining the PACTA Uganda Mental Health and Addiction Community Camp 2026 – Tackle Sickle Cell Africa
-
Nov 17, 2026, 05:30Nathan Connell: Women’s Hematology Summit 2027 to Address Hematologic Health Across the Lifespan
-
Nov 17, 2026, 05:25Mane Kurghinyan: Representing Armenia and HemAI Dynamics at the Falling Walls Lab Global Finale 2026
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH